Effects of Lansoprazole on Sitagliptin Glucose-lowering Ability in Healthy Males: a Randomised Crossover Study
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Oral hypoglycemic medications sometimes do not control type 2 diabetes well. Proton pump
inhibitors (PPIs) as adjunctive therapy might improve diabetes control and could enhance the
hypoglycemic activity of DPP4, but there is little clinical data on efficacy of this
therapeutic strategy. The investigators sought to examine the effect of PPI lansoprazole,
DPP-4 inhibitor sitagliptin, and their combination therapy on insulin and glucose regulation
in healthy subjects in oral glucose tolerance (OGTT).